Slate Path Capital’s Korsana Biosciences KRSA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
– Sell
-51,126
Closed -$927K – 56
2024
Q3
$927K Hold
51,126
– – 0.01% 67
2024
Q2
$823K Hold
51,126
– – 0.02% 58
2024
Q1
$1.15M Hold
51,126
– – 0.02% 57
2023
Q4
$1.2M Hold
51,126
– – 0.03% 54
2023
Q3
$1.22M Hold
51,126
– – 0.03% 43
2023
Q2
$1.47M Hold
51,126
– – 0.05% 42
2023
Q1
$3.11M Hold
51,126
– – 0.15% 35
2022
Q4
$4.7M Hold
51,126
– – 0.25% 36
2022
Q3
$6.16M Hold
51,126
– – 0.4% 32
2022
Q2
$3.93M Hold
51,126
– – 0.25% 35
2022
Q1
$7.94M Hold
51,126
– – 0.41% 29
2021
Q4
$12.3M Hold
51,126
– – 0.65% 26
2021
Q3
$22M Hold
51,126
– – 1% 24
2021
Q2
$27.9M Buy
51,126
+6,868
+16% +$3.01M 1.56% 17
2021
Q1
$17.3M Hold
44,258
– – 1.12% 19
2020
Q4
$19M Hold
44,258
– – 1.03% 15
2020
Q3
$37.7M Buy
44,258
+35,715
+418% +$28.6M 2.14% 14
2020
Q2
$7.07M Hold
8,543
– – 0.42% 20
2020
Q1
$3.17M Buy
+8,543
New +$4.27M 0.24% 23
2019
Q4
– Sell
-6,286
Closed -$10.7M – 28
2019
Q3
$10.7M Buy
6,286
+1,186
+23% +$1.79M 0.71% 15
2019
Q2
$8.18M Buy
+5,100
New +$10.1M 0.37% 19

Other funds holding KRSA

Slate Path Capital's KRSA Position: Q4 2024 in Review

Slate Path Capital sold out of Korsana Biosciences (KRSA) in Q4 2024, closing a stake of 51,126 shares — an estimated $927K sold.

Slate Path Capital first reported a position in KRSA in Q2 2019 and held it in 21 quarters. The position peaked at $37.7M in Q3 2020. 18 funds tracked by Wall St. Rank hold KRSA as of Q4 2024.

  • Slate Path Capital reported no remaining Korsana Biosciences position as of Q4 2024 after selling out during the quarter.
  • Slate Path Capital sold 51,126 Korsana Biosciences shares in Q4 2024, an estimated $927K.
  • Slate Path Capital first reported a position in Korsana Biosciences in Q2 2019 and held it in 21 quarters.
  • Slate Path Capital's Korsana Biosciences position peaked at $37.7M in Q3 2020.
  • 18 funds tracked by Wall St. Rank held Korsana Biosciences as of Q4 2024.

Based on Slate Path Capital's 13F filing for Q4 2024, filed 14 Feb 2025.